Chronic Non-Allergic Rhinitis (Investigational Adjunct)
Investigational adjunct for chronic non-allergic rhinitis; intranasal corticosteroids, intranasal antihistamines, and trigger avoidance remain evidence-based.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for chronic non-allergic rhinitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (investigational). No controlled trials. Evidence-based first-line management is identifying and avoiding triggers, intranasal ipratropium for rhinorrhea, intranasal azelastine for mixed symptoms, intranasal corticosteroids, saline irrigation, and capsaicin nasal spray for refractory vasomotor-type rhinitis.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Facial bite scarring at periorbital or paranasal placement sites
- Risk of post-session epistaxis
- Wer dies nicht in Betracht ziehen sollte
- Patients who have not tried intranasal ipratropium, azelastine, and corticosteroid combinations
- Patients with structural nasal pathology (deviated septum, polyps) not yet evaluated by ENT
- Patients with possible allergic rhinitis that has not been ruled out by allergy testing
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Was Sie Ihren Kliniker fragen sollten
- Has allergic rhinitis been ruled out by allergy testing?
- Has structural nasal pathology been evaluated by ENT?
- Have I tried the standard intranasal therapies adequately?
- What is the published evidence base for leeches in non-allergic rhinitis?
- Where exactly will leeches be placed on the face?
- What is the bleeding-control plan for nosebleeds?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Heavy or persistent nosebleed
- Unilateral persistent nasal symptoms (could indicate tumor)
- Facial swelling affecting vision or breathing
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for rhinitis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace topical intranasal therapies.
- It does not change the underlying autonomic or neurogenic dysregulation.
- It does not address structural pathology that may need surgery.
- It does not have controlled-trial evidence.
Sicherheits-Querverweise
Clinical Profile
- Category
- ent
- ICD-10
- J31.0, J30.0
- Safety tier
- medium
Evidence Summary
Chronic non-allergic rhinitis (vasomotor, gustatory, occupational, hormonal subtypes) is nasal congestion and rhinorrhea without IgE-mediated allergy. Evidence-based management is intranasal corticosteroids (mometasone, fluticasone), intranasal antihistamines (azelastine), intranasal anticholinergics (ipratropium), saline irrigation, and trigger avoidance. Allergy testing is required to confirm non-allergic phenotype. No published controlled trials of hirudotherapy exist for chronic non-allergic rhinitis. Facial placement is uniquely high-risk (nasal vasculature, infraorbital nerve). The bridge of the nose, eyebrow region, and forehead have appeared in some traditional-medicine descriptions, but these are anatomically dangerous.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Allergic rhinitis not yet trialed on intranasal corticosteroid and antihistamine
- Nasal polyps requiring surgical evaluation
- Facial placement (nose, forehead, eyebrow region)
- Active sinusitis
- Chronic rhinosinusitis with mucopurulent drainage
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.